Pilot study identifies hemoglobin and biomarkers for thrombosis risk stratification in sickle cell anemia, suggesting pathways for improved management.
Key Points
Elevated hemoglobin and absence of hydroxyurea were linked to higher thrombosis risk in sickle cell anemia patients.
The model achieved an AUC of 0.83, indicating robust predictive capability for thrombosis risk.
Statistical analyses employing logistic regression revealed significant associations between thrombosis and several clinical biomarkers.
Further validation in larger cohorts is needed to establish a clinically useful risk stratification tool for thrombosis in sickle cell anemia.